Rakuten Medical’s Post

The neoadjuvant combination of camrelizumab, nab-paclitaxel & cisplatin demonstrated statistically significant enhancements in pCRs compared with solitary chemotherapy in resectable locally advanced esophageal squamous cell carcinoma. https://lnkd.in/ei3axH2q

Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/jbM5hq

Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/RpId8e

Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. At #ASCO24, Dr. David Cognetti presented the updated safety and efficacy findings from an interim evaluation of Rakuten Medical’s open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Based on these results, Rakuten Medical plans to initiate a new phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox

Clinical response of T3 squamous cell carcinoma of the tongue, treated with neoadjuvant pembrolizumab-carboplatin-paclitaxel. Significant reduction of the tumor size.

Cohort study aims to establish whether anterior vs posterior tumor extension may represent a prognostic factor in oral tongue and floor squamous cell carcinoma. https://ja.ma/3ODk2Q9

In a pre-specified interim analysis of the Phase 2 KEYNOTE-B84 study evaluating pepinemab in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for immunotherapy of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), pepinemab induced lymphoid structures were associated with an approximate doubling of objective responses (ORR) and progression free survival (PFS) relative to historical results with checkpoint monotherapy in patients with hard-to-treat tumors that express low levels of PD-L1 (CPS<20). https://bit.ly/47fm7Z9 #SITC23 #SITC2023 #Bcells

✨#HotPaper #mdpicancers☑️ "Human Papillomavirus and Survival of Sinonasal Squamous Cell Carcinoma Patients: A Systematic Review and Meta-Analysis" Find the full paper here⏩ https://lnkd.in/d7ZAVaKr

High Tumor Burden: The Kryptonite of CAR T-Cell Therapy? This review focuses on linking the efficacy and safety of CAR T-cell therapy with tumor burden by JAMA

Ophthopedia Update:Squamous cell carcinoma on the head of a primary pterygium: Eye, Published online: 23 April 2024; doi:10.1038/s41433-024-03095-0Squamous cell carcinoma on the head of a primary pterygium #Ophthalmology #Eye #Ophthotwitter